Ipriflavone directly inhibits osteoclastic activity.
Ipriflavone, an isoflavone derivative, is a new drug used in an attempt to decrease bone loss in osteoporosis. Experimental studies have shown that this compound acts by inhibiting osteoclastic bone resorption both in vivo and in vitro, but the mechanism of its inhibitory action on resorbing cells remains unclear. Using bone resorption assays, video image analysis together with measurements of intracellular free calcium in isolated osteoclasts, we show here that IP directly inhibits osteoclastic activity by the modulation of intracellular free calcium.
Albanese
C V
CV
Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy.
Cudd
A
A
Argentino
L
L
Zambonin-Zallone
A
A
MacIntyre
I
I
D000818:Animals; D000831:Animals, Newborn; D001862:Bone Resorption; D002118:Calcium / Q000378:metabolism*; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D016257:Fura-2; D007529:Isoflavones / Q000494:pharmacology*; D007700:Kinetics; D010010:Osteoclasts / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D007529:Isoflavones; C018986:ipriflavone; D002118:Calcium; D016257:Fura-2